Barnor Jacob S, Habu Yuichiro, Yamamoto Norio, Miyano-Kurosaki Naoko, Ishikawa Koichi, Yamamoto Naoki, Takaku Hiroshi
Department of Life and Environmental Science, Chiba Institute of Technology, Narashino, Chiba, Japan.
Antiviral Res. 2009 Aug;83(2):156-64. doi: 10.1016/j.antiviral.2009.04.008. Epub 2009 May 3.
Combinatorial therapies for the treatment of HIV-1 infection are effective for reducing patient viral loads and slowing the progression to AIDS. Our strategy was based on an anti-HIV-1 shRNA vector system in which HIV-1 vif-shRNA was fused to a decoy TAR RNA (mini-TAR RNA) to generate vif-shRNA-decoy TAR RNA under the control of the human U6 Pol III promoter. Upon expression in human cells, the RNA molecule was cleaved into its component parts, which inhibited HIV-1 replication in a synergistic manner. This chimeric RNA expressed a dual RNA moiety and greatly enhanced the inhibition of HIV-1 replication under the production of resistant virus by short interference RNA (siRNA) in long-term culture assays. We suggest that this technique provides a practical basis for the application of siRNA-based gene therapy in the treatment of HIV/AIDS.
用于治疗HIV-1感染的联合疗法对于降低患者病毒载量和减缓向艾滋病的进展是有效的。我们的策略基于一种抗HIV-1 shRNA载体系统,其中HIV-1 vif-shRNA与一个诱饵TAR RNA(微型TAR RNA)融合,以在人U6 Pol III启动子的控制下产生vif-shRNA-诱饵TAR RNA。在人细胞中表达后,RNA分子被切割成其组成部分,这些部分以协同方式抑制HIV-1复制。这种嵌合RNA表达了一种双RNA部分,并在长期培养试验中通过短干扰RNA(siRNA)在产生抗性病毒的情况下极大地增强了对HIV-1复制的抑制作用。我们认为,这项技术为基于siRNA的基因疗法在治疗HIV/AIDS中的应用提供了实际基础。